BURLINGTON, Mass., August 12, 2026
Bone Biologics Corporation announced that its rhNELL-1 protein has achieved a validated shelf life of 32 months, representing a manufacturing and development milestone for the company’s lead orthobiologic program. The extended stability period is supported by third-party stability data and is expected to provide greater flexibility in the manufacturing, storage and distribution of rhNELL-1 as the company advances its development program. Bone Biologics said the milestone could support more efficient lot sizing, inventory management, distribution planning and supply-chain operations as its first-in-human NB1 clinical study progresses. The latest achievement builds on previously validated shelf-life milestones of 12, 18, 24 and 29 months.
rhNELL-1 Supports Development of NB1 Bone Regeneration Product
rhNELL-1 is the active protein component of NB1, Bone Biologics’ lead product candidate for bone regeneration in spinal fusion procedures. NB1 combines rhNELL-1 with demineralized bone matrix, with the goal of providing controlled bone regeneration during spinal fusion. Bone Biologics is currently conducting a multicenter, prospective, randomized pilot clinical study evaluating NB1 in up to 30 subjects with degenerative disc disease undergoing transforaminal lumbar interbody fusion. The study is being conducted in Australia and represents an important step in translating the company’s preclinical work on NELL-1 into human clinical development. The company’s current focus is on spinal fusion, while its broader rights to NELL-1 technology include potential applications in trauma and osteoporosis..
Extended Shelf Life Could Improve Manufacturing Flexibility
The achievement of a 32-month validated shelf life provides practical advantages for the development and potential future manufacturing of rhNELL-1. A longer validated storage period can allow manufacturers to plan larger production lots, reduce pressure around product expiration and improve inventory management across clinical and commercial supply chains. Bone Biologics said the new milestone follows the 29-month shelf-life validation announced in May 2026 and the 24-month milestone achieved in December 2025. While shelf-life validation does not demonstrate clinical efficacy, it is an important CMC and manufacturing-readiness milestone for an investigational biologic product, particularly as development moves toward larger-scale clinical studies and eventual commercialization.
Advertisement
Bone Biologics Advances Toward Larger-Scale Clinical Development
The 32-month stability milestone comes as Bone Biologics continues advancing NB1 through its first-in-human development program. The company is using the current pilot study to evaluate its bone-regeneration approach in patients undergoing spinal fusion, while continuing to strengthen the manufacturing infrastructure supporting rhNELL-1. If clinical development demonstrates that NB1 can safely and effectively promote bone regeneration and improve spinal fusion outcomes, the technology could potentially address an important need in the orthobiologics and spine fusion market. However, the product remains investigational, and the shelf-life achievement itself does not establish clinical effectiveness or regulatory approval. Further clinical data will be required to determine whether rhNELL-1/NB1 can successfully advance toward pivotal studies and eventual commercialization.
Source:Bone Biologics,,press release
